Deferasirox versus deferoxamine [6]

Blood

Volumn 108, Issue 2, 2006, Pages 774-775

  Martin, Mike G ^a   Arcasoy, Murat O ^b  

^a Duke Box 31303   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; IRON;

BETA THALASSEMIA; BIOASSAY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IRON BLOOD LEVEL; LETTER; LIVER CIRCULATION; PATIENT COMPLIANCE; POPULATION EXPOSURE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VALIDITY;

EID: 33745967933     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-002436     Document Type: Letter

References (2)

1. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107:3455-3462. (Prepublished online December 13, 2005, as DOI 10.1182/blood-2005-08-3430.)
2. Rothwell PM. External validity of randomized clinical trials: to whom do the results of this trial apply? Lancet. 2005;65:82-93.